CL-275838

CL-275838 is a small molecule compound with a pyrazolo(1,5-a)pyrimidine core structure. It was developed as a potential memory-enhancing and cognition-enhancing agent, with additional reported antidepressant activity. The drug has been studied in both healthy volunteers and patients with dementia (including Alzheimer’s disease and vascular dementia) for its effects on cognitive function. Pharmacokinetic studies indicate rapid absorption after oral administration, dose-proportional increases in plasma concentration up to 100 mg, and elimination half-lives ranging from approximately 18 to 21 hours for the parent compound in young adults (longer in elderly subjects). Clinical trials have shown some improvement in cognitive measures at higher doses but also noted mild side effects such as drowsiness or agitation at these doses. The mechanism of action is not fully elucidated but is presumed to involve central nervous system targets relevant to memory and mood enhancement[1][2][3][4][5][7].